Last reviewed · How we verify
Correction Factor
Correction Factor is a diabetes management tool or educational intervention designed to help patients calculate appropriate insulin dosing adjustments based on blood glucose levels.
Correction Factor is a diabetes management tool or educational intervention designed to help patients calculate appropriate insulin dosing adjustments based on blood glucose levels. Used for Type 1 diabetes mellitus — insulin dose adjustment, Type 2 diabetes mellitus — insulin dose adjustment.
At a glance
| Generic name | Correction Factor |
|---|---|
| Also known as | Rapid acting regular insulin |
| Sponsor | Hennepin Healthcare Research Institute |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
A correction factor (also called insulin sensitivity factor) is a clinical parameter used in insulin therapy to determine how many blood glucose mg/dL units will be lowered by one unit of insulin. This tool assists patients and healthcare providers in personalizing insulin dose adjustments to achieve target blood glucose control. It is typically part of basal-bolus insulin regimens or insulin pump therapy protocols.
Approved indications
- Type 1 diabetes mellitus — insulin dose adjustment
- Type 2 diabetes mellitus — insulin dose adjustment
Common side effects
Key clinical trials
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- The Influence of Chemotherapy on Position Sense
- The Advisor Pro Direct Study (NA)
- Performance and Safety Evaluation of the EkiYou V2 Application in Patients With Diabetes Using Multiple Daily Insulin Injections (EkiYou-Study1) (NA)
- Clinical Evaluation of the Nuance Audio Hearing Aid in Adults With Mild to Moderate Hearing Difficulties (NA)
- EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation (NA)
- The Effect of Kinesio Taping Applied to Operating Room Nurses on Low Back Pain, Fatigue, and Sleep Quality (NA)
- In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Correction Factor CI brief — competitive landscape report
- Correction Factor updates RSS · CI watch RSS
- Hennepin Healthcare Research Institute portfolio CI